Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial - Archive ouverte HAL Access content directly
Journal Articles European Journal of Heart Failure Year : 2021

Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

(1) , (2, 3, 4, 5) , (6) , (7) , (8) , (9, 10, 11) , (12) , (8) , (13, 14) , (15) , (16, 17) , (8) , (18) , (19, 20, 21) , (22, 23, 24, 25) , (8) , (26, 27) , (28) , (29)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Javed Butler
Ileana L Piña
Bertram Pitt

Abstract

Aims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enrol ~820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to ≥50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi Use Score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive HF medication. Conclusion: The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use.
Fichier principal
Vignette du fichier
ejhf.2386.pdf (1.59 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03467277 , version 1 (06-12-2021)

Identifiers

Cite

Javed Butler, Stefan D Anker, Tariq Jamal Siddiqi, Andrew J S Coats, Fabio Dorigotti, et al.. Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. European Journal of Heart Failure, 2021, ⟨10.1002/ejhf.2386⟩. ⟨hal-03467277⟩
86 View
39 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More